Posted on 05/02/2010 in Pharmaceutical Company Product News Pfizer has forged a new partnership with QIAGEN's fully owned subsidiary DxS, which will see the two work together to develop a companion diagnostic test kit for PF-04948568 (CDX-110).
The compound is an immunotherapy vaccine currently in the development stages for the treatment of glioblastoma multiforme (GBM).
PF-04948568 (CDX-110) is a peptide vaccine which targets an epidermal growth factor receptor that is only present in cancer cells.
QIAGEN's assay is designed to identify those patients whose tumours express this mutation, therefore allowing for more focused treatment.
Pfizer received the worldwide licence to PF-04948568 (CDX-110) from Celldex Therapeutics in April 2008.
Dr Stephen Little, vice-president of personalised healthcare for QIAGEN, commented: "We are very pleased to have signed this agreement with Pfizer, as it is another important step toward the realisation of personalised medicine."
Earlier this week, QIAGEN unveiled its latest product - the QIAsymphony AS. Other news stories from 05/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
